Anna Antony

Anna Antony is a Senior Lecturer at the School of Clinical Sciences at Monash Health, Monash University. She holds an MBBS (Hons) from Monash University and an MSc in Epidemiology (2018). Her research focuses on psoriatic arthritis, clinical trial methodologies, and outcome assessment in autoimmune diseases. She leads multiple international studies as Primary Chief Investigator, including trials evaluating novel biologic therapies like bimekizumab and upadacitinib for psoriatic arthritis and axial spondyloarthritis. Her work contributes to UN Sustainable Development Goals related to health and well-being.

Key projects include a multicenter randomized trial comparing bimekizumab with risankizumab (2025-2030), a phase 3 study on deucravacitinib for treatment-naive patients (2022-2027), and a longitudinal observational cohort study funded by Arthritis Australia (2020). Her research emphasizes structural damage assessment in joints, patient demographics in clinical trials, and standardized outcome measures for psoriatic arthritis.

Publications include high-impact reviews in Seminars in Arthritis and Rheumatism and The Lancet Rheumatology, focusing on trial design, radiographic standards, and patient-reported outcomes. She collaborates with global networks like GRAPPA-OMERACT and the PROMPT Study Group to advance rheumatology research.